Skip to main content
. 2022 Jan 11;2022(1):CD010037. doi: 10.1002/14651858.CD010037.pub4

Lijnen 1995.

Study characteristics
Methods Double‐blind, placebo‐controlled parallel‐group cross‐over study
The trial was conducted in Belgium.
Participants 32 male participants
Age: 24 ± 1 (range 20 ‐ 44 years) and weight 75.9 ± 1.3 kg
Interventions Intervention group: 1 g elemental calcium as calcium gluconate powder twice a day (morning and evening)
Control group: placebo with the same orange flavour as intervention
Trial duration: 16 weeks
Outcomes Blood pressure recorded in standing position
Intracellular cationic concentrations
Transmembrane cation transport systems
Plasma total and ionised calcium
Calciotropic hormones
Notes This study was supported by Boehringer Ingelheim.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel (performance bias)
All outcomes Low risk A double‐blind placebo‐control parallel‐group. The calcium supplement and placebo were both orange flavour.
Blinding of outcome assessment (detection bias)
All outcomes Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes Low risk All participants randomised were included in the results.
Selective reporting (reporting bias) Low risk Primary outcomes results were reported.
Other bias Low risk Baseline characteristics were similar between calcium and placebo groups.